Nursing

Adverse effect

Dupilumab

Surgery

Atopic dermatitis

Visual analogue scale

Dermatology

Placebo

Immunology

Alternative medicine

Monoclonal antibody

Quality of life (healthcare)

Internal medicine

Eczema Area and Severity Index

Monoclonal

Medicine

Dermatology Life Quality Index

Disease

Severity of illness

Antibody

Randomized controlled trial

Pathology

New England Journal of Medicine

Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis. In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis.

Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus